Cowen initiates coverage on Rocket Pharmaceuticals (NASDAQ: RCKT) with a Outperform rating.Analyst Phil Nadeau commented, "RCKT has 5 gene therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE